<DOC>
	<DOCNO>NCT02280616</DOCNO>
	<brief_summary>The purpose study assess efficacy low high dose budesonide effervescent tablet oral viscous budesonide suspension vs. placebo induction treatment active eosinophilic esophagitis .</brief_summary>
	<brief_title>Budesonide Effervescent Tablets vs. Viscous Budesonide Suspension v . Placebo Eosinophilic Esophagitis</brief_title>
	<detailed_description />
	<mesh_term>Esophagitis</mesh_term>
	<mesh_term>Eosinophilic Esophagitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Major Signed inform consent Male female patient , 18 75 year age Confirmed clinicopathological diagnosis EoE accord establish diagnostic criterion : ( A ) Clinical symptom esophageal dysfunction ( B ) Peak eosinophils â‰¥ 15 least 1 highpower field ( hpf ) Active symptomatic histological EoE baseline Major Clinically endoscopically suspicion gastroesophageal reflux disease , achalasia , sklerodermia Gastroesophageal reflux disease PPIresponsive esophageal eosinophilia Other clinical evident cause EoE esophageal eosinophilia Any concomitant esophageal disease relevant gastrointestinal disease ( celiac disease , inflammatory bowel disease , oropharyngeal esophageal bacterial , viral , fungal infection ) Any relevant systemic disease ( e.g. , AIDS , active tuberculosis ) Abnormal hepatic function screen visit , liver cirrhosis , portal hypertension Abnormal renal function screen History cancer last five year ( except nonmetastatic cancer , e.g. , basalioma ) History esophageal surgery time esophageal dilation procedure within last 8 week prior screen visit Upper gastrointestinal bleeding within 8 week prior screen visit Concomitant , within 4 week prior screen visit , treatment systemic therapy reason may affect assessment primary secondary endpoint , i.e. , systemic glucocorticoid , histamine antagonist , mast cell stabilizer , leukotriene receptor antagonist , biologics , immunosuppressant Concomitant , within 2 week prior screen visit , treatment topical therapy reason may affect assessment primary secondary endpoint , i.e. , topical glucocorticoid inhale sodium cromoglycate Installation dietary restriction within 4 week prior screen visit treatment Intake grapefruit contain food beverage treatment study medication Known intolerance/hypersensitivity study drug Existing intend pregnancy breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>